Page 344 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

322 PART III Therapeutic Modalities for the Cancer Patient

118. McMillan CJ, Livingston A, Clark CR, et al.: Pharmacokinetics of 139. Platt SR, Adams V, Garosi LS, et al.: Treatment with gabapentin of 11
intravenous tramadol in dogs, Can J Vet Res 72:325–331, 2008. dogs with refractory idiopathic epilepsy, Vet Rec 159:881–884, 2006.
119. Giorgi M, Saccomanni G, Łebkowska-Wieruszewska B, et al.: 140. Verdu B, Decosterd I, Buclin T, et al.: Antidepressants for the treat-
VetBooks.ir Pharmacokinetic evaluation of tramadol and its major metabolites 141. Kautio AL, Haanpää M, Saarto TKE: Amitriptyline in the treat-
ment of chronic pain, Drugs 68:2611–2632, 2008.
after single oral sustained tablet administration in the dog: a pilot
study, Vet J 180:253–255, 2009.
120. Giorgi M, Del Carlo S, Saccomanni G, et al.: Pharmacokinetics of ment of chemotherapy-induced neuropathic symptoms, Anticancer
Res 29:2601–2606, 2008.
tramadol and its major metabolites following rectal and intrave- 142. Kautio AL, Haanpää M, Leminen A, et al.: Amitriptyline in the
nous administration in dogs, NZ Vet J 57:146–152, 2009. prevention of chemotherapy-induced neuropathic symptoms, Anti-
121. Giorgi M, Del Carlo S, Saccomanni G, et al.: Pharmacokinetic and cancer Res 29:2601–2606, 2009.
urine profile of tramadol and its major metabolites following oral 143. Chew DJ, Buffington CA, Kendall MS, et al.: Amitriptyline treat-
immediate release capsules administration in dogs, Vet Res Commun ment for severe recurrent idiopathic cystitis in cats, J Am Vet Med
33:875–885, 2009. Assoc 213:1282–1286, 1998.
122. Giorgi M, De Carlo S, Saccomanni G, et al.: Biopharmaceutical 144. Cashmore RG, Harcourt-Brown TR, Freeman PM, et al.: Clini-
profile of tramadol in the dog, Vet Res Commun 33:189–192, 2009. cal diagnosis and treatment of suspected neuropathic pain in three
123. Perez TE, Mealey KL, Grubb TL, et al.: Tramadol metabolism dogs, Aust Vet J 87:45–50, 2009.
to o-desmethyl tramadol (M1) and n-desmethyl tramadol (M2) 145. Norkus C, Rankin D, Kukanich B: Pharmacokinetics of intrave-
by dog liver microsomes: species comparison and identification nous and oral amitriptyline and its active metabolite nortriptyline
of responsible canine cytochrome P450s, Drug Metab Dispos in Greyhound dogs, Vet Anaesth Analg 42:580–589, 2015.
44:1963–1972, 2016. 146. Challapalli V, Tremont-Lukats IW, McNicol ED, et al.: Systemic
124. Pypendop BH, Ilkiw JE: Pharmacokinetics of tramadol, and its administration of local anesthetic agents to relieve neuropathic
metabolite O-desmethyl-tramadol, in cats, Pharmacetical Sci 2:52– pain, Cochrane Database Syst Rev 4, 1996.
59, 2007. 147. Ann Fleming J, David O’ Connor B: Use of lidocain patches
125. Pypendop BH, Siao KT, Ilkiw JE: Effects of tramadol hydrochlo- for neuropathic pain in a comprehensive cancer centre, Pain Ress
ride on the thermal threshold in cats, Am J Vet Res 70:1465–1470, Manag 14:381–388, 2009.
2009. 148. Weiland L, Croubels S, Baert K, et al.: Pharmacokinetics of a lido-
126. Monteiro BP, Klinck MP, Moreau M, et al.: Analgesic efficacy of caine patch 5% in dogs, J Vet Med Ser A Physiol Pathol Clin Med
tramadol in cats with naturally occurring osteoarthritis, PLoS One 53:34–39, 2006.
12:1–13, 2017. 149. Ko JCH, Maxwell LK, Abbo LA, et al.: Pharmacokinetics of lido-
127. Woolf CJ, Thompson SWN: The induction and maintenance of caine following the application of 5% lidocaine patches to cats,
central sensitization is dependent on N-methyl-d-aspartic acid J Vet Pharmacol Ther 31:359–367, 2008.
receptor activation; implications for the treatment of post-injury 150. Ko J, Weil A, Maxwell L, Kitao THT: Plasma concentrations of
pain hypersensitivity states, Pain 44:293–299, 1991. lidocaine in dogs following lidocaine patch application, J Vet Phar-
128. Graven-Nielsen T, Arendt-Nielsen L: Peripheral and central sen- macol Ther 43:280–283, 2007.
sitization in musculoskeletal pain disorders : an experimental 151. Weil AB, Ko J, Inoue T: The use of lidocaine patches, Compend
approach, Curr Rheumatol Rep 4:313–321, 2002. Contin Educ Vet 29: 208–210, 212, 214–216, 2007.
129. Wagner AE, Walton JA, Hellyer PW, et al.: Use of low doses of 152. Firestein G, Paine M, Littman B: Gene expression (collagenase,
ketamine administered by constant rate infusion as an adjunct for tissue inhibitor of metalloproteinases, complement, and hla-dr) in
postoperative analgesia in dogs, J Am Vet Med Assoc 221:72–75, rheumatoid arthritis and osteoarthritis synovium, Arthritis Rheum
2002. 34:1094–1105, 1991.
130. Slingsby LS, Waterman-Pearson AE: The post-operative analgesic 153. Fakih M, Johnson CS, Trump DL: Glucocorticoids and treatment
effects of ketamine after canine ovariohysterectomy - a comparison of prostate cancer: a preclinical and clinical review, Urology 60:553–
between pre- or post-operative administration, Res Vet Sci 69:147– 561, 2002.
152, 2000. 154. Sibilia J: Corticosteroids and inflammation, Rev Prat 53:495–501,
131. Eisenberg E, Pud D: Can patients with chronic neuropathic pain 2003.
be cured by acute administration of the NMDA receptor antago- 155. Mensah-Nyagan AG, Meyer L, Schaeffer V, et al.: Evidence for a
nist amantadine? Pain 74:337–339, 1998. key role of steroids in the modulation of pain, Psychoneuroendocri-
132. Lascelles BDX, Hansen BD, Thomson A, et al.: Evaluation of a nology 34, 2009
digitally integrated accelerometer-based activity monitor for the 156. Melcangi RC: Neuroprotective effects of neuroactive steroids in the
measurement of activity in cats, Vet Anaesth Analg 35:173–183, spinal cord and peripheral nerves, J Mol Neurosci 28:1–2, 2006.
2008. 157. Jones JS, Brown MD, Bermingham M, et al.: Efficacy of paren-
133. Vernier VG, Harmon JB, Stump JM, et al.: The toxicologic and teral dexamethasone to prevent relapse after emergency department
pharmacologic properties of amantadine hydrochloride, Toxicol treatment of acute migraine, Acad Emerg Med 10:542, 2003.
Appl Pharmacol 15:642–665, 1969. 158. Rowe BH, Blitz S, Coleman IEM: Dexamethasone in migraine
134. KuKanich B, Papich MG: Plasma profile and pharmacokinetics relapse: a randomized, placebo-controlled clinical trial, Acad Emerg
of dextromethorphan after intravenous and oral administration in Med 13:S16, 2006.
healthy dogs, J Vet Pharmacol Ther 27:337–341, 2004. 159. Fiesseler FW, Shih R, Szucs P, et al.: Steroids for migraine head-
135. Vollmer KO KE: Pharmacokinetics and metabolism of gabapentin aches: a randomized double-blind, two-armed, placebo-controlled
in rat, dog and man, Arzneimittelforschung 36:830–839, 1986. trial, J Emerg Med 40:463–468, 2011.
136. Radulovic LL, Türck D, von Hodenberg AL, et al.: Disposition 160. Wareham D: Postherpetic neuralgia, Clin Evid 12:1182–1193,
of gabapentin (neurontin) in mice, rats, dogs, and monkeys, Drug 2004.
Metab Dispos 23:441–448, 1995. 161. Takeda K, Sawamura S, Sekiyama H, et al.: Effects of methylpred-
137. Pypendop BH, Siao KT, Ilkiw JE: Thermal antinociceptive effect nisolone on neuropathic pain and spinal glial activation in rats,
of orally administered gabapentin in healthy cats, Am J Vet Res Medscape 100:1249–1257, 2004.
71:1027–1032, 2010. 162. Maranzano E, Latini P, Beneventi S, et al.: Radiotherapy without
138. Siao KT, Pypendop BHIJ: Pharmacokinetics of gabapentin in cats, steroids in selected metastatic spinal cord compression patients: a
Am J Vet Res 71:817–821, 2010. phase II trial, Am J Clin Oncol 19:179–183, 1996.